Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients
Quick Facts
- Publication title: Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients
- Journal: Transl Androl Urol
- Year: 2022
- DOI: 10.21037/tau-21-1136
- PMID/PMCID: 35280667; PMC8899142
Research overview
The present study showed that the detection of urine-derived exosomal AR-V7 provides a sensitive and feasible clinical workflow. We performed a non-invasive urine-derived exosomal AR-V7 analysis of mCRPC patients.
Key findings
Urine is the ideal biological sample for exosome separation and AR full-length analysis.
4% (11 of 34) of the mCRPC patients' urine samples.
Study design
A total of 34 mCRPC patients were recruited including 16 patients treated with abiraterone (ABI) with stable prostate-specific antigen (PSA)/radiograph response (the ABI-Sta group) and 18 were resistant to abiraterone (the ABI-Res group).
Urine was collected from patients and healthy control patients for the analysis.
Exosomal ribonucleic acid was isolated from urine.
Echo Biotech Role
Echo Biotech's specific contribution should be verified from the full text or internal project record.
Related platforms: To Be Verified
Related services and capabilities: Role Not Identified
References
Original publication: Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients Transl Androl Urol. 2022. DOI: 10.21037/tau-21-1136. PMID/PMCID: 35280667; PMC8899142.